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Stereotactic brachytherapy (SBT) has been described in several publications as an effective, minimal invasive and
safe highly focal treatment option in selected patients with well circumscribed brain tumors <4 cm. However, a still
ongoing discussion about indications and technique is hindering the definition of a clear legitimation of SBT in
modern brain tumor treatment. These controversies encompass the question of how intense the irradiation should
be delivered into the target volume (dose rate). For instance, reports about the use of high does rate (HDR)
implantation schemes ( >40 cGy/h) in combination with adjuvant external beam radiation and/or chemotherapy
for the treatment of malignant gliomas and metastases resulted in increased rates of radiation induced adverse
tissue changes requiring surgical intervention. Vice versa, such effects have been only minimally observed in
numerous studies applying low dose rate (LDR) regiments (3–8 cGy/h) for low grade gliomas, metastases and other
rare indications. Besides these observations, there are, however, no data available directly comparing the long term
incidences of tissue changes after HDR and LDR and there is, furthermore, no evidence regarding a difference
between temporary or permanent LDR implantation schemes. Thus, recommendations for effective and safe
implantation schemes have to be investigated and compared in future studies.
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stereotactic brachytherapy (SBT)) has been applied for
intrinsic brain tumors and metastases for more than four
decades in numerous patients. The majority of studies
reported about the application of high-dose rate (HDR)
iodine-125 implants (40-70 cGy/h) for high-grade gli-
omas, including two prospective randomized trials,
which compared standard treatment regiments with/
without SBT [1,2]. This approach, however, was asso-
ciated with high incidence of radiation induced adverse
effects requiring repeated surgery and failed to proof any
significant oncological benefit as compared to standard
treatment regiments. Another approach using SBT was
the application of low-dose rate (LDR) implants
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reproduction in any medium, provided the ormetastases which demonstrated in several very recent
publications to be associated with only little permanent
deficits and almost an absence of radiation induced ne-
crosis [3-17].
A recent comprehensive review on SBT for brain
tumors by Schwarz et al. [17] summarized almost all pub-
lished knowledge about this technique with the clear
intention to clarify and overcome some of the preconcep-
tions associated with brachytherapy. The authors eluci-
dated in this well written and thoroughly investigated
review the rationale, physical and biological characteris-
tics, surgical technique, indications, complications and
– most important – evidence in a critical and comprehen-
sive manner. Especially laudable is the authors´ clear
recommendation to LDR implantation schemes instead of
HDR as used by US groups in treatment protocols for
high grade gliomas which caused unacceptable high rates
of treatment relevant radiation induced necrosis [1,18,19].
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low-grade - brain tumors. Based on this experience we
would like to contribute the following aspects to the
discussion:
1. Schwarz et al. mention an increased risk for prolonged
edema and late radiation necrosis when using permanent
implantation as compared to temporary LDR implanta
tion and refer to non human experimental data of the
mid 1980´s [20-22].Our applied prospective treatment
protocol for low grade gliomas (WHO grades I and II)
stipulates permanent implantation of iodine-125 seeds
with initial dose rates of 0.02 – 0.03 Gy/h (prescribed
surface dose: 50–65 Gy). With this strategy we very
rarely observe prolonged edema or late radiation necrosis
[3,4,6,7].Interestingly, the rate of surgically relevant cysts
after temporary implantation of iodine-125 seeds for
low grade gliomas in a pediatric population as reported
by Korinthenberg et al. [10] was three times as high
(33/94 patients= 35.1 %) as in a similar population
treated with permanent implants by our group (16/142
Patients= 11.3 %) [3].
Furthermore, Kreth et al. evaluated risk factors for
SBT in 515 patients with low grade brain tumors and
mentioned no significant difference of temporary vs.
permanent LDR implantation schemes with regard to
complications [23].Thus, our clinical experience as
well as the reported findings in the literature does not
support at all the authors´ reservation towards
permanent implantation SBT.
However, a critical comparison of long term results with
regard to radiation induced tissue changes between
permanent vs. temporary LDR implantation schemes is
yet not available but necessary to ultimately clarify this
controversy [24].
2. To complement the review’s physics part we may
indicate that the Task Group 43 of the AAPM
(American Academy of Physical Medicine) introduced
(beginning in 1995) an internationally accepted standard
for the dosimetry of iodine-125 seeds allowing to
compare dosimetry between different countries and
groups [25-30].
3. Further, we concur with Schwarz et al. on the
importance of post operative imaging (either by
intraoperative X-ray or by postoperative CT scanning)
to confirm an accurate location of the implanted
seeds, thus allowing a precise comparison with the
irradiation plan at any time [31].
Ultimately, publications of this high quality keep one
of oldest and most sophisticated neurosurgical technique
in a vivid discussion as a minimal invasive, safe, and
highly effective neuro-oncological local treatment option
for selected patient populations.Abbreviations
SBT: Stereotactic BrachyTherapy; HDR: High Does Rate; LDR: Low Dose Rate;
cGy/h: Centigray Per Hour; AAPM: American Academy of Physical Medicine.
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